Detalhe da pesquisa
1.
TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens.
Gynecol Oncol
; 112(1): 179-84, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18937971
2.
TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study.
BMC Cancer
; 8: 27, 2008 Jan 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-18230133
3.
PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients.
Cancer Biol Ther
; 8(1): 21-6, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19029838